TY - JOUR
T1 - Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results
AU - Madsbad, Sten
N1 - Keywords: Anti-Obesity Agents; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Hemoglobin A, Glycosylated; Humans; Peptides; Receptors, Glucagon; Venoms
PY - 2009
Y1 - 2009
N2 - The GLP-1 analogues exenatide and liraglutide stimulate insulin secretion and inhibit glucagon output in a glucose-dependent manner, slow gastric emptying and decrease appetite. The injectable glucagon-like peptide-1 (GLP-1) receptor agonist exenatide significantly improves glycaemic control, with average reductions in HbA1c of about 1.0% point, fasting plasma glucose of about 1.4 mmol l(-1), and causes a weight loss of approximately 2-3 kg after 30 weeks of treatment. The adverse effects are transient nausea and vomiting. The long-acting once-daily human GLP-1 receptor agonist liraglutide reduces HbA1c by about 1.0-2.0% point, weight by 1-3 kg and seems to have fewer gastrointestinal side effects than exenatide. The final place of the GLP-1 receptor agonists in the diabetes treatment algorithm will be clarified when we have long-term trials with cardiovascular end-points and data illustrating the effects on the progression of type 2 diabetes.
AB - The GLP-1 analogues exenatide and liraglutide stimulate insulin secretion and inhibit glucagon output in a glucose-dependent manner, slow gastric emptying and decrease appetite. The injectable glucagon-like peptide-1 (GLP-1) receptor agonist exenatide significantly improves glycaemic control, with average reductions in HbA1c of about 1.0% point, fasting plasma glucose of about 1.4 mmol l(-1), and causes a weight loss of approximately 2-3 kg after 30 weeks of treatment. The adverse effects are transient nausea and vomiting. The long-acting once-daily human GLP-1 receptor agonist liraglutide reduces HbA1c by about 1.0-2.0% point, weight by 1-3 kg and seems to have fewer gastrointestinal side effects than exenatide. The final place of the GLP-1 receptor agonists in the diabetes treatment algorithm will be clarified when we have long-term trials with cardiovascular end-points and data illustrating the effects on the progression of type 2 diabetes.
U2 - 10.1016/j.beem.2009.03.008
DO - 10.1016/j.beem.2009.03.008
M3 - Journal article
C2 - 19748064
SN - 1521-690X
VL - 23
SP - 463
EP - 477
JO - Best Practice & Research: Clinical Endocrinology & Metabolism
JF - Best Practice & Research: Clinical Endocrinology & Metabolism
IS - 4
ER -